• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NeuroImmune Pharm Ther . Structural Brain Abnormalities and Neuropsychiatric Symptoms in Post-COVID Condition

tetano

Editor, Senior Moderator
NeuroImmune Pharm Ther


. 2025 Nov 17:10.1515/nipt-2025-0012.
doi: 10.1515/nipt-2025-0012. Online ahead of print. Structural Brain Abnormalities and Neuropsychiatric Symptoms in Post-COVID Condition

Meghann Ryan[SUP] 1 2 [/SUP], Jared Thomas[SUP] 1 3 [/SUP], Jeremy Wang[SUP] 1 [/SUP], Huajun Liang[SUP] 1 [/SUP], Eric Cunningham[SUP] 1 [/SUP], Thomas Ernst[SUP] 1 [/SUP], Linda Chang[SUP] 1 2 4 5 [/SUP]



Affiliations
Abstract

Objectives: We aimed to cross-sectionally and longitudinally compare brain morphometry and neuropsychiatric symptoms, and evaluate their relationship, in participants with Post-Coronavirus Disease Condition (PCC) and healthy Controls.
Methods: At Baseline, 29 PCC (19 female; average age=42.4±12.2 years; 242±156 days since infection) and 25 Controls (14 female; 44.1±12.3 years) completed the NIH Toolbox Emotion, Motor and Cognition Batteries; Patient Reported Outcomes Measurement Information System (PROMIS); and structural brain MRI (thickness, areas, volumes). We compared neurobehavioral performance on the NIH Toolbox and PROMIS and structural brain morphometry for 34 cortical regions and 8 subcortical volumes, between PCC and matched Controls at Baseline (~8 months post-infection) and 11 PCC and 7 Controls at a Follow-Up Visit (~3 years post-infection).
Results: At Baseline, PCC had significantly larger putamen and amygdala (FDR-corrected p=0.04; +5.3 and 5.9%) and a trend for larger hippocampus and accumbens (uncorrected-p=0.012 and 0.027, +5.1 and 12.9%) than Controls. PCC also tended to have 4 thicker cortices (p=0.010-0.049; +3.6-6.5%), 6 larger surface areas (p=0.009-0.023; +5.9-8.6%), and 9 larger cortical volumes (p=0.003-0.008; +4.2-10.7%). These abnormal measures were associated with more anxiety, depression, and pain (r=0.5-0.75; p=0.005-0.04). At Follow-Up, PCC had more sadness, fear, pain, and fatigue compared to Controls. However, group differences in morphometry diminished and PCC neurobehavioral performance tended to improve.
Conclusions: Structural abnormalities in PCC suggest compensatory processes such as enhanced myelination or neurogenesis, rather than neuroinflammation, which in turn may contribute to persistent neurobehavioral symptoms. However, these alterations and symptoms may improve three years after infection.

Keywords: Brain morphometry; Longitudinal; NIH Toolbox; PROMIS; Post-COVID Condition.

 
Back
Top